Skip to Content

Alterity Therapeutics Ltd PRNAF

Morningstar Rating
$0.00 0.00 (16.98%)
View Full Chart
Unlock Our Analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

PRNAF is trading at a 57% discount.
Price
$0.00
Fair Value
$1.53
Uncertainty
Extreme
1-Star Price
$6.32
5-Star Price
$2.45
Economic Moat
Rtnz
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PRNAF is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.01
Day Range
$0.000.00
52-Week Range
$0.000.03
Bid/Ask
$0.00 / $0.04
Market Cap
$10.63 Mil
Volume/Avg
10,000 / 10,843

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield
Dividend Yield (Forward)
Total Yield

Company Profile

Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
11

Valuation

Metric
PRNAF
Price/Earnings (Normalized)
Price/Book Value
0.86
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
PRNAF
Quick Ratio
5.58
Current Ratio
6.17
Interest Coverage
Quick Ratio
PRNAF

Profitability

Metric
PRNAF
Return on Assets (Normalized)
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
PRNAF

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRRsyf$453.9 Bil
VRTX
Vertex Pharmaceuticals IncYzbpsnt$90.4 Bil
REGN
Regeneron Pharmaceuticals IncYmvjdtv$88.1 Bil
SGEN
Seagen Inc Ordinary SharesMhwvj$40.3 Bil
MRNA
Moderna IncVqfl$30.1 Bil
ARGX
argenx SE ADRGvltk$26.1 Bil
BNTX
BioNTech SE ADRPvnf$23.6 Bil
ALNY
Alnylam Pharmaceuticals IncKjpjn$20.6 Bil
BMRN
Biomarin Pharmaceutical IncJpxpfh$16.9 Bil
INCY
Incyte CorpSgtjgr$12.0 Bil